araag2/HINT huggingface dataset:
Clinical trial NCT00768300 (phase 3, status: terminated)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: ambrisentan, placebo
SMILES: COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or females from 40 to 80 years of age

          -  Diagnosis of IPF

          -  Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT)
             scan of less than or equal to 5%

          -  Willing and able to have 2 right heart catheterizations performed

          -  Willing to have monthly lab tests to monitor liver function

          -  Able to perform the 6 minute walk test (indicated adequate physical function)

          -  Must have meet lung function requirements

          -  Normal liver function tests

          -  Negative serum pregnancy test

          -  Willing to use at least 2 reliable methods of contraception

          -  Able to understand and willing to sign informed consent form

        Exclusion Criteria:

          -  No restrictive lung disease (other than usual interstitial pneumonia or IPF)

          -  No obstructive lung disease

          -  No recent or active respiratory exacerbations

          -  No recent hospitalization for an IPF exacerbation

          -  No recent history of alcohol abuse

          -  Chronic sildenafil (or same drug class) use for pulmonary hypertension

          -  Chronic treatment with certain medications for IPF within 30 days of randomization

          -  No other serious medical conditions
Clinical trial NCT00090051 (phase 3, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: rituximab, fludarabine phosphate, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years

          -  Established diagnosis of B-cell CLL by NCI Working Group criteria

          -  ≤1 previous line of chemotherapy

          -  Expected survival >6 months

          -  Acceptable hematologic status, liver function, renal function, and pulmonary function

          -  Negative serum pregnancy test for both pre-menopausal women and for women who are < 2
             years after the onset of menopause

          -  Written informed consent

        Exclusion Criteria:

          -  Prior treatment with interferon, rituximab or other monoclonal antibody

          -  Prior allogeneic bone marrow transplant (BMT) or autologous BMT or peripheral stem
             cell transplant (PBSCT) or patients who are considered to be candidates for allogeneic
             or autologous BMT or PSCT as assessed by their treating physician

          -  Fertile men or women of childbearing potential not using adequate contraception

          -  Severe Grade 3 or 4 non-hematological toxicity or prolonged (> 2 weeks) Grade 3 or 4
             cytopenia on prior fludarabine or nucleoside analogue regimen

          -  History of fludarabine-induced or clinically significant autoimmune cytopenia

          -  History of other malignancies within 2 years prior to study entry, except for
             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin
             cancer; low-grade early stage localized prostate cancer treated surgically with
             curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated
             with lumpectomy alone with curative intent.

          -  Medical conditions requiring long term use (> 1 month) of systemic corticosteroids

          -  Active bacterial, viral, or fungal infection requiring systemic therapy

          -  Severe cardiac disease

          -  Seizure disorders requiring anticonvulsant therapy

          -  Severe chronic obstructive pulmonary disease with hypoxemia

          -  Uncontrolled diabetes mellitus or hypertension

          -  Transformation to aggressive B-cell malignancy.

          -  Known infection with HIV, HCV, or hepatitis B

          -  Treatment with any other investigational agent, or participation in another clinical
             trial within 30 days prior to entering this study

          -  Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

          -  Any co-existing medical or psychological condition that would preclude participation
             in the study or compromise ability to give informed consent
Clinical trial NCT00603291 (phase 3, status: completed)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: lorcaserin 10 mg once daily (qd), lorcaserin 10 mg twice a day (bid), matching placebo
SMILES: COC1=CC=CC=C1OCC(O)CO, COC1=CC=CC=C1OCC(O)CO, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Overweight/obese men and women with type 2 diabetes mellitus that is managed with oral
             anti-hyperglycemic agent(s).

          -  Body mass index (BMI) 27 to 45 kg/m2, inclusive.

          -  Ability to complete a 1 year study

        Exclusion Criteria:

          -  Pregnancy

          -  Use of insulin in any form, exenatide (Byetta) or pramlintide (Symlin) within 3 months
             prior to screening

          -  History of symptomatic heart valve disease

          -  Serious or unstable current or past medical conditions
Clinical trial NCT00264550 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: golimumab 100 mg, golimumab 50 mg, methotrexate, placebo injection, placebo capsules
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria
             of the ACR) for at least 3 months prior to screening

          -  Must have been treated with and tolerated methotrexate (MTX) at a dose of at least 15
             mg/week for at least 3 months prior to screening, and have a MTX dose of >=15 mg/week
             and <=25 mg/week and stable for at least 4 weeks prior to screening

          -  Have active RA as defined by persistent disease activity with at least 4 swollen and 4
             tender joints, at the time of screening and baseline, and at least 2 of the following
             4 criteria: a)C-reactive protein (CRP) >=1.5 mg/dL at screening or erythrocyte
             sedimentation rate (ESR) by Westergren method of >= 28 mm in the first hour at
             screening or baseline, b)Morning stiffness of >= 30 minutes at screening and baseline,
             c)Bone erosion by x-ray and/or magnetic resonance imaging (MRI) prior to first
             administration of study agent, d)Anti-cyclic citrullinated peptide (anti-CCP)
             antibody-positive or rheumatoid factor (RF) positive at screening

          -  If using oral corticosteroids, must be on a stable dose equivalent to <= 10 mg of
             prednisone/day for at least 2 weeks prior to first administration of study agent

          -  Are considered eligible according to specified tuberculosis (TB) screening criteria

        Exclusion Criteria:

          -  Have inflammatory diseases other than RA that might confound the evaluation of the
             benefit of golimumab therapy

          -  Have had treatment with disease-modifying anti-rheumatic drugs (DMARDs)/systemic
             immunosuppressives other than MTX, during the 4 weeks prior to the first
             administration of study agent

          -  Have had prior treatment with biologic anti-tumor necrosis factor (TNF) drugs
             (infliximab, etanercept, adalimumab)

          -  Have had history of, or ongoing, chronic or recurrent infectious disease.

          -  Have serious infection within 2 months prior to first administration of study agent

          -  Have a history of latent or active granulomatous infection, including TB,
             histoplasmosis, or coccidioidomycosis, prior to screening
Clinical trial NCT00251719 (phase 3, status: completed)
Conditions: esophagitis, reflux, esophagitis, peptic
ICD codes: K21.9, K21.00, K21.01, B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: dexlansoprazole mr, dexlansoprazole mr, lansoprazole
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have endoscopically confirmed erosive esophagitis as defined by the Los
             Angeles (LA) Classification Grading System (A-D).

        Exclusion Criteria:

          -  Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.)
             pylori.

          -  Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2)
             receptor antagonists or sucralfate, drugs with significant anticholinergic effects,
             misoprostol or prokinetics

          -  Use of antacids [except for study supplied Gelusil®]

          -  Need for continuous anticoagulant therapy (Blood Thinners)

          -  Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus

          -  History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of
             mucosal tissue near the lower esophageal sphincter)

          -  Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory
             condition

          -  History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer

          -  Acute upper gastrointestinal (UGI) hemorrhage within 4 weeks of the Screening
             endoscopy
Clinical trial NCT00490919 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: buprenorphine transdermal system, placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with moderate to severe chronic low back pain (lasting several hours daily)
             as their predominant pain condition for at least 3 months prior to screening,

          -  Subjects treated within the 14 days prior to screening with nonopioid therapy only, or
             with therapy including opioids at a dose of <5 mg oxycodone (or equivalent) per day,

          -  Subjects whose low back pain is not adequately controlled with non-opioid analgesic
             medication and who the Investigator feels are appropriate candidates for
             around-the-clock opioid therapy

        Exclusion Criteria:

          -  Subjects who had a surgical procedure directed towards the source of back pain within
             6 months of screening or planned during the study conduct period,

          -  Subjects who are allergic to buprenorphine or who had a history of allergies to other
             opioids,

          -  Subjects who have allergies or other contraindications to transdermal delivery systems
             or patch adhesives.

        Other protocol-specific inclusion/exclusion criteria may apply.
Clinical trial NCT00362206 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: fenofibrate/simvastatin, fenofibrate/simvastatin, pravastatin
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Mixed dyslipidemia

        Exclusion Criteria:

          -  Known hypersensitivity to fenofibrates or simvastatin or pravastatin

          -  Pregnant or lactating women

          -  Contra-indication to fenofibrate or simvastatin or pravastatin

          -  Unstable or severe cardiac disease
Clinical trial NCT00427362 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: adalimumab
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Active psoriatic arthritis defined by >= 3 tender or painful joints and >= 3 swollen
             joints despite standard psoriatic arthritis therapy

          -  Has had an unsatisfactory response or intolerance to at least two prior or ongoing
             DMARDs (one of which has to be methotrexate)

        Exclusion Criteria:

          -  Has a history of cancer or other than certain skin or cervical cancers

          -  Has a history of, or current acute inflammatory joint disease of origin other than
             PsA, e.g., systemic lupus erythematosus etc.

          -  Has other, unstable diseases, including congestive heart failure, inflammatory bowel
             disease, recent stroke, leg ulcers or other condition which would put the subject at
             risk

          -  History of active tuberculosis, history of histoplasmosis or listeriosis

          -  Latent TB or risk factors for the activation of latent TB, e.g. previous exposure to
             TB, and has not initiated TB prophylaxis prior to the first adalimumab treatment
Clinical trial NCT01104779 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: cariprazine, placebo
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have provided informed consent prior to any study specific procedures

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia (paranoid type,
             disorganized type, catatonic type or undifferentiated type), as confirmed by the
             Structured Clinical Interview for Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition (SCID)

          -  Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCIPANSS)
             total score ≥ 80 and ≤ 120

          -  Diagnosis of schizophrenia for a minimum of 1 year before Visit 1

          -  Patients with normal physical examination, laboratory, vital signs,and/ or
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of Schizoaffective disorder, schizophreniform
             disorder, other psychotic disorders other than schizophrenia, or bipolar I or II
             disorder

          -  Patients in their first episode of psychosis

          -  Pregnant, breast-feeding, and/or planning to become pregnant and/or breastfeed during
             the study

          -  Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and
             other cognitive disorders

          -  Known or suspected borderline or antisocial personality disorder or other DSM-IV-TR
             axis II disorder of sufficient severity to interfere with participation in this study

          -  Substance abuse or dependence within the prior 3 months
Clinical trial NCT00098124 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: milnacipran hydrochloride
SMILES: CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR)
             Criteria

        Exclusion Criteria:

          -  Psychiatric illness

          -  Depression

          -  Suicidal risk

          -  Substance abuse

          -  Pulmonary dysfunction

          -  Renal impairment

          -  Active cardiac disease

          -  Liver disease

          -  Autoimmune disease

          -  Cancer

          -  Sleep apnea

          -  Inflammatory bowel disease
Clinical trial NCT00361504 (phase 3, status: completed)
Conditions: osteoarthritis, hip, osteoarthritis, knee, lower back pain, pain
ICD codes: M16.9, M16.0, M16.10, M16.11, M16.12, M16.30, M16.31, M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone cr, tapentadol (cg5503) er
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O, CC[C@H]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of knee or hip osteoarthritis with history of pain at the reference
             joint for at least 3 months or clinical diagnosis of low back pain of benign origin
             for at least 3 months

          -  Must be dissatisfied with their current analgesic therapy (e.g. Non-steroidal
             anti-inflammatory drugs NSAIDS, COX-2 inhibitors, opioids, paracetamol/acetaminophen

          -  Have a pain intensity >4 on Numerical Rating Scale

        Exclusion Criteria:

          -  Life-long history of seizure disorder or epilepsy

          -  Any of the following within one year: mild/moderate traumatic brain injury, stroke,
             transient ischemic attack, and brain neoplasm

          -  Severe traumatic brain injury within 15 years (consisting of more than one of the
             following: brain contusion (injuries resulting in hemorrhage), intracranial hematoma,
             unconsciousness or post traumatic amnesia lasting for more than 24 hours) or residual
             sequelae suggesting transient changes in consciousness

          -  History of malignancy within past 2 years, with exception of a successfully treated
             basal cell carcinoma

          -  Presence of significant pain associated with conditions other than osteoarthritis or
             low back pain that could confound the assessment or self-evaluation of pain
Clinical trial NCT00628862 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: formoterol turbuhaler® 4.5mg, formoterol turbuhaler® 9 mg, turbuhaler® placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged above 40 with a clinical diagnosis of COPD and current COPD
             symptoms

          -  Current or previous smoker with a smoking history of 10 or more pack years

          -  Lung function parameters: FEV1/FVC < 70%, post-bronchodilator and post-bronchodilator
             FEV1 < 80% of predicted normal value

        Exclusion Criteria:

          -  History and/or current clinical diagnosis of asthma or atopic diseases such as
             allergic rhinitis

          -  Use of inhaled glucocorticosteroids within 4 weeks prior to Visit 2

          -  Any relevant cardiovascular disorder as judged by the investigator or any current
             respiratory tract disorder other than COPD.
Clinical trial NCT00254891 (phase 3, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: pf-3512676 + paclitaxel + carboplatin, paclitaxel + carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Reason stopped: 
    see termination reason in detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced Non-Small-Cell Lung Cancer (NSCLC) stage IIIB with pleural effusion or stage
             IV

          -  No prior systemic treatment for Non-Small-Cell Lung Cancer (NSCLC)with chemotherapy,
             immunotherapy, biologic response modifiers or other investigational drugs

          -  Eastern Cooperative Oncology Performance Status (ECOG PS) 0 or 1

        Exclusion Criteria:

          -  Small cell or carcinoid lung cancer

          -  Known Central Nervous System (CNS) metastasis

          -  Pre-existing auto-immune or antibody mediated diseases
Clinical trial NCT00365352 (phase 3, status: completed)
Conditions: restless legs syndrome
ICD codes: G25.81
Drugs: xp13512 600mg, xp13512 1200mg, placebo
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with primary RLS, based on the International RLS Study Diagnostic Criteria.

        Exclusion Criteria:

          -  A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of
             RLS;

          -  Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's
             Disease, Multiple Sclerosis, dyskinesias, and dystonias);

          -  Abnormal laboratory results, electrocardiogram (ECG) or physical findings;

          -  Pregnant or lactating women;

          -  Women of childbearing potential who are not practicing an acceptable method of birth
             control.
Clinical trial NCT00605280 (phase 2/phase 3, status: completed)
Conditions: macular edema associated with diabetes mellitus
ICD codes: J95.851, D76.2, E87.71, J65, M04.2, A80.0, G44.82
Drugs: standard of care, macugen
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  macular edema associated with diabetes

          -  visual acuity between 20/50 and 20/200

        Exclusion Criteria:

          -  recent laser therapy in the eye

          -  recent signs of uncontrolled diabetes

          -  blood pressure worse than 160/100

          -  severe cardiac disease
Clinical trial NCT01355367 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: nifedipine (adalat, baya1040)
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who complete the 8 week double blind treatment phase of Study 13176 and for
             whom the test drug is tolerable

        Exclusion Criteria:

          -  Patients with expected difficulties for the continuous 1 year follow up